| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Stroke. 2004;35:e159.)
© 2004 American Heart Association, Inc.
Research Reports |
From the Departments of Neurology (J.C.A., J.E.D., J.C., G.A.R.), Cell Biology and Physiology (G.A.R.), and Neuroscience (G.A.R.), the University of New Mexico School of Medicine, Albuquerque, NM; Veterans Administration Health Center (J.C.A.), Albuquerque, NM; the Department of Neurology (J.A.K., J.F.Q.), Oregon Health Science University, Portland, Ore; the Department of Medicine (R.M.C.), University of Alberta, Edmonton, AB, Canada; Extracellular Matrix Pathology Section (W.G.S.-S.), Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, Md.
Correspondence to Dr John C. Adair, Department of Neurology, University of New Mexico Health Sciences Center, Albuquerque, NM 87131. E-mail adair.john{at}albuquerque.va.gov
Background and Purpose Vascular causes of dementia are increasing in importance because of the aging of the population. Biological markers to distinguish patients with vascular dementia (VaD) from Alzheimer disease (AD) would be very useful. Because cerebrovascular disease increases expression of brain matrix metalloproteinases (MMPs) and tissue inhibitors to metalloproteinases (TIMPs), we hypothesized that MMPs would be elevated in the cerebrospinal fluid (CSF) of patients with VaD, but not in patients with AD.
Methods Fifteen patients with VaD were identified, including dementia caused by multiple infarcts and progressive dementia caused by disease of the small cerebral blood vessels. Patients were followed-up for 4 to 10 years to confirm the diagnosis. Thirty patients with AD were also studied. Patients had CSF collected at their initial evaluation. Gelatinase A (MMP-2) and gelatinase B (MMP-9) were quantified by gelatin-substrate zymography, and TIMPs were measured by reverse zymography. Control CSF was obtained from neurologically normal subjects.
Results MMP-9 levels were significantly elevated in the CSF of VaD patients compared either to those with AD (P<0.0001) or to controls. MMP-2, TIMP-1, and TIMP-2 were similar in patient groups and controls.
Conclusions Patients with multiinfarct and small vessel VaD have elevated levels of MMP-9 in the CSF compared with AD and controls. Although CSF MMP-9 increases in other neurological conditions and is not specific for VaD, it could provide an additional biological marker for the separation of patients with VaD and AD.
Key Words: matrix metalloproteinase dementia
This article has been cited by other articles:
![]() |
E. H. Lo and G. A. Rosenberg The Neurovascular Unit in Health and Disease: Introduction Stroke, March 1, 2009; 40(3_suppl_1): S2 - S3. [Full Text] [PDF] |
||||
![]() |
G. A. Rosenberg Inflammation and White Matter Damage in Vascular Cognitive Impairment Stroke, March 1, 2009; 40(3_suppl_1): S20 - S23. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Tian, S. A. Greenberg, S. W. Kong, J. Altschuler, I. S. Kohane, and P. J. Park Discovering statistically significant pathways in expression profiling studies PNAS, September 20, 2005; 102(38): 13544 - 13549. [Abstract] [Full Text] [PDF] |
||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |